Evidence map›Paper›PMID 42034881›Full record

ArticleInternational urology and nephrology2026

Serum complement C3 as a candidate biomarker for monitoring progression from chronic kidney disease to kidney failure.

Cheng Chen, Xiaoyan Xie, Xuemei Chen, Jinke Geng, Yuqi He, Qi Jing, Yonghua Chen, Mutian Han

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Cheng Chen *Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 80 Tianedang Road, Suzhou, 215104, Jiangsu, China.
Xiaoyan Xie *Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 80 Tianedang Road, Suzhou, 215104, Jiangsu, China.
Xuemei Chen *Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, Jiangsu, China.
Jinke GengDepartment of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 80 Tianedang Road, Suzhou, 215104, Jiangsu, China.
Yuqi HeDepartment of Transfusion, The Lu'an Hospital Affiliated to Anhui Medical University, The Lu'an People's Hospital, Lu'an, Anhui, China.
Qi JingDepartment of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 80 Tianedang Road, Suzhou, 215104, Jiangsu, China.
Yonghua ChenDepartment of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 80 Tianedang Road, Suzhou, 215104, Jiangsu, China.
Mutian HanDepartment of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 80 Tianedang Road, Suzhou, 215104, Jiangsu, China. Jiopkuy@aliyun.com.

Funding

Research Project on Innovation in Hospital Management JSYGY-3-2025-028the Gusu Health Talent Project 2024-180the Suzhou "KeJiaoQiangWei" Youth Project QNXM2024034Young Talent Development Project GSKY20240511
6 · The paper itself

Abstract

objectiveTo monitor the progression of chronic kidney disease to kidney failure is a pressing clinical challenge given its increasing incidence.

methodsIn a retrospective cohort of 764 patients admitted to our hospital between June 2021 and June 2024, we performed a comprehensive analysis of serum complement C3/C4 levels.

resultsLongitudinal assessment revealed a progressive, dose-dependent decline in serum C3 that correlated with disease advancement from renal insufficiency to chronic renal failure and ultimately to kidney failure. To further investigate the role of C3, we utilized an adenine-induced nephropathy model in mice. C3

conclusionsSerum C3 may represent a candidate biomarker worthy of further prospective validation for tracking the progression of CKD. Our research findings are expected to establish a novel prognostic framework for risk stratification of CKD patients through continuous serum C3 monitoring, offering a critical window for early intervention in end-stage renal disease.

Indexed as

Complement C3Kidney Failure, ChronicRenal Insufficiency, ChronicAnimalsBiomarkersB-LymphocytesDisease ProgressionFemaleHumansMaleMiceRetrospective StudiesBiomarkersComplement C3B cellChronic kidney diseaseComplement C3Uremia

Identifiers

PMID42034881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.